Concord Biotech Intrinsic Value
Concord Biotech (CONCORDBIO) median intrinsic value is ₹2383.40 from 10 valuation models (range ₹410–₹3413), vs current price ₹1365.00 — +74.6% upside (Trading Below Calculated Value), margin of safety 42.7%. Analyse Concord Biotech shareholding analysis to track promoter, FII and institutional holdings.
CONCORDBIO Valuation Methods Summary — DCF, Graham Number & P/E
Concord Biotech intrinsic value across 10 models vs current price ₹1365.00 — upside/downside and value range per method. Read CONCORDBIO dividend payout details for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹744.48 | ₹595.58 - ₹893.38 | -45.5% | EPS: ₹33.84, Sector P/E: 22x |
| Book Value Method | asset | ₹3412.50 | ₹3071.25 - ₹3753.75 | +150.0% | Book Value/Share: ₹1831.82, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2480.00 | ₹2232.00 - ₹2728.00 | +81.7% | Revenue/Share: ₹1240.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2730.00 | ₹2457.00 - ₹3003.00 | +100.0% | EBITDA: ₹536.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2383.40 | ₹1906.72 - ₹2860.08 | +74.6% | CF Growth: 6.4%, Discount: 15% |
| PEG Ratio Method | growth | ₹409.50 | ₹368.55 - ₹450.45 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹522.83 | ₹470.55 - ₹575.11 | -61.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2730.00 | ₹2457.00 - ₹3003.00 | +100.0% | ROE: 17.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1180.99 | ₹1062.89 - ₹1299.09 | -13.5% | EPS: ₹33.84, BVPS: ₹1831.82 |
| Dividend Yield Method | dividend | ₹409.50 | ₹368.55 - ₹450.45 | -70.0% | DPS: ₹7.55, Target Yield: 2.5% |
CONCORDBIO Intrinsic Value vs Market Price — All Valuation Models
Concord Biotech fair value range ₹410–₹3413 vs current market price ₹1365.00 across 10 valuation models. For current market price and key ratios, visit Concord Biotech stock price NSE.
CONCORDBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Concord Biotech median intrinsic value ₹2383.40, current price ₹1365.00 — Trading Below Calculated Value by 74.6%, margin of safety 42.7%.
What is the intrinsic value of CONCORDBIO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Concord Biotech (CONCORDBIO) is ₹2383.40 (median value). With the current market price of ₹1365.00, this represents a +74.6% variance from our estimated fair value.
The valuation range spans from ₹409.50 to ₹3412.50, indicating ₹409.50 - ₹3412.50.
Is CONCORDBIO undervalued or overvalued?
Based on our multi-method analysis, Concord Biotech (CONCORDBIO) appears to be trading below calculated value by approximately 74.6%.
CONCORDBIO Financial Health — Key Ratios vs Industry Benchmarks
Concord Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 24.51 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
CONCORDBIO Cash Flow Quality — Operating & Free Cash Flow
Concord Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹267 Cr | ₹196 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹245 Cr | ₹165 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹266 Cr | ₹189 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹246 Cr | ₹167 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹208 Cr | ₹152 Cr | Positive Free Cash Flow | 8/10 |